[Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study].
Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation. The patients were between 10 and 17 years of age. Pseudomonas infection was present in 75% of these patients. Despite frequent persistence of the pathogens, clinical improvement was noted in 75% of the treated children. A definite increase of the average MIC was not seen in 20 cases of persisting strains. No serious side effects occurred during the 14-day oral treatment course. Ciprofloxacin is a useful alternative to conventional parenteral treatment with antibiotics in patients suffering from cystic fibrosis and infections of the airways.
Sollich
V
V
Klinik für Kinderheilkunde, Medizinischen Akademie Magdeburg.
Klöditz
E
E
Schuster
R
R
Handrick
W
W
Brömme
S
S
Rumler
W
W
Patsch
R
R
Kharari
H
H
Spencker
F B
FB
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D002939:Ciprofloxacin